2008 Dr. Greg Albers and Dr. Roland Bammer develop Rapid technology, the first fully automated image processing platform, at Stanford University with software engineer Matus Straka and funding from Sequoia Capital founder Don Valentine.
2009 Rapid MRI software installed in eight US and one European center for the NIH-sponsored DEFUSE 2 study.
2012 Dr. Albers and Dr. Bammer co-found the company iSchemaView (now named RapidAI®) and purchase the rights to Rapid technology from Stanford University.
2012 The DEFUSE 2 study shows that by using Rapid MRI, physicians can identify stroke patients who respond favorably to endovascular clot removal up to 12 hours after stroke onset. Since then, RapidAI technology has been validated in more than a dozen multicenter clinical trials. (The recommended treatment window has since been extended to 24 hours.)
2012 Rapid CTP developed and installed in more than 70 North American and European sites for the SWIFT PRIME, EXTEND, and EXTEND-IA trials.
2013 Rapid CTP and Rapid MRI receive FDA clearance, allowing the platform to be used in hospitals throughout the U.S.
2014 SWIFT PRIME and EXTEND-IA trials document the highest favorable outcome rates ever obtained in a stroke trial and validate the use of Rapid CTP to select patients for thrombectomy within 6 hours of symptom onset.
2015 American Heart Association guidelines endorse thrombectomy as a new standard of care for stroke patients who can be treated up to 6 hours after onset. Rapid platform installed in more than 100 stroke centers.
2016 Rapid platform selected as the exclusive imaging selection method for the late-window trials, DAWN and DEFUSE 3.
2017 The Rapid platform achieves CE Mark certification, paving the way for use in the European Union.
2018 Based on the DAWN and DEFUSE 3 clinical trials that used Rapid imaging to select stroke patients for late-window treatment, the American Heart and American Stroke associations revise guidelines, extending the treatment window for acute stroke patients from 6 to 24 hours.
2018 The Rapid platform is approved for use in Canada, Australia, and New Zealand. Don Listwin is named CEO. Rapid ASPECTS announced, provides automated scoring to assess early signs of brain infarction. Rapid CTA receives FDA clearance.
2019 The EXTEND trial doubles the treatment window for intravenous tPA using Rapid CTP and Rapid MRI.
2019 Rapid CTA receives CE approval, becoming the first advanced imaging product indicated for localization of a detected large vessel occlusion (LVO). Mexico, Brazil, Japan, Israel, and Vietnam join the list of 50+ countries that approve the use of Rapid platform.
2020 Rapid ICH launches worldwide, using artificial intelligence to quickly notify physicians of possible intracranial hemorrhage.
2020 RapidAI acquires Endovantage, an innovator in comprehensive aneurysm management—expanding scope from stroke to aneurysm.
2020 RapidAI Insights launches—offering a suite of reports and analytics on Rapid scan, treatment, and outcomes data.
AI-powered Rapid ASPECTS becomes the first ever neuroimaging solution to receive FDA clearance in the CADx (Computer-Assisted Diagnostic software) category.
2020 RapidAI hits a major milestone with over 1 million recorded scans and is used in 1,600+ hospitals worldwide.
2020 Rapid LVO receives FDA clearance for identification of suspected large vessel occlusions.
2020 RapidAI receives $25 million in Series B funding to accelerate the company’s strategic growth initiatives and expand AI-enhanced cerebrovascular imaging around the world.
2021 RapidAI grows its global footprint to over 100 countries with its technology utilized in more than 1,800 hospitals.
2021 RapidAI announces a new partnership with Penumbra to develop solutions to enable faster clinical decision-making for pulmonary embolism (PE) diagnosis and procedures.
2021 RapidAI is named the exclusive advanced neuroimaging partner for the World Stroke Organization and SIECV stroke center certification program in Latin America.

Rapid Aneurysm - Video